What question did this study set out to answer?

To evaluate whether long-term probucol treatment prevents secondary cardiovascular events in high-risk patients with heterozygous familial hypercholesterolemia.

January 1, 2008Journal of Atherosclerosis and ThrombosisOpen Access

Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan

View Full Paper

Ask AI

Bookmark

Why the study?

Does long-term probucol treatment prevent secondary cardiovascular events in patients with heterozygous familial hypercholesterolemia?

Population

Patients with heterozygous familial hypercholesterolemia in Japan, specifically a higher cardiovascular risk…

Design

Cohort

Authors

SYShizuya YamashitaUniversité Claude Bernard Lyon 1 HBHideaki BujoToho University HAHidenori AraiGeneral / Preventive / Lipids

Discussion

Member takes

Implication

May support targeted probucol use in high-risk heterozygous FH; leaves open randomized confirmation of benefit.

Key Points

To evaluate whether long-term probucol treatment prevents secondary cardiovascular events in high-risk patients with heterozygous familial hypercholesterolemia.
Cohort study analyzing patients with heterozygous familial hypercholesterolemia receiving long-term probucol therapy in Japan.
Long-term probucol treatment qualitatively demonstrated protective effects against secondary cardiovascular attacks in a higher-risk population.
Specific quantitative event rates, hazard ratios, confidence intervals, and p-values were not reported in the abstract.

Structured PICO

Does long-term probucol treatment prevent secondary cardiovascular events in patients with heterozygous familial hypercholesterolemia?

Population

Patients with heterozygous familial hypercholesterolemia (FH) in Japan, specifically a higher cardiovascular risk population

Intervention

Long-term probucol treatment

Outcome

Secondary cardiovascular events (secondary attack)hard clinical

Long-term probucol treatment may be effective for secondary prevention of cardiovascular events in high-risk patients with heterozygous familial hypercholesterolemia.

Cite This Study

Yamashita et al. (2008) studied this question.

synapsesocial.com/papers/69d53062418584181da66ffc https://doi.org/10.5551/jat.e610

Topics

Women and heart disease Cardiovascular prevention

View Full Paper

Ask AI

Bookmark

Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider